A open-label Phase 2 clinical study evaluating the efficacy and safety of TYRA-300 in participants with FGFR3-altered low-grade, IR NMIBC
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs TYRA-300 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms SURF-302
- 23 Jan 2025 New trial record
- 10 Jan 2025 According to a Tyra Biosciences media release, the U.S. FDA cleared its Investigational New Drug application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). This program will be led by Dr. Erik Goluboff principal investigator of this trial. First patient expected to be dosed in SURF302 in Q2 2025. The study will enroll up to 90 participants primarily from USA.